Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Pathology

• Publication date

  2011-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/path.2912PMID 21598254PMCID PMC4484598
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How does diabetes accelerate Alzheimer disease pathology?

  2010cited by this paper
• Insulin-Resistant Brain State after Intracerebroventricular Streptozotocin Injection Exacerbates Alzheimer-like Changes in Tg2576 AβPP-Overexpressing Mice

  2010cited by this paper
• Brain glucose transporters, O‐GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease

  2009cited by this paper
• Deficiency of a β-arrestin-2 signal complex contributes to insulin resistance

  2009cited by this paper
• Chronic beta-AR activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized female rats.

  2009cited by this paper
• The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid.

  2009cited by this paper
• Insulin Signaling in Sporadic Alzheimer’s Disease

  2009cited by this paper
• ‘ Protection of synapses against Alzheimer ’ slinked toxins : Insulin signaling prevents the pathogenic binding of A oligomers

  2009cited by this paper
• Insulin is a Two-Edged Knife on the Brain

  2009cited by this paper
• Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease.

  2009cited by this paper
• Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes

  2009cited by this paper
• Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers

  2009cited by this paper
• Risk of Incident Alzheimer's Disease in Diabetic Patients: A Systematic Review of Prospective Trials

  2009cited by this paper
• Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.

  2009cited by this paper
• Neurodegenerative disease: Diabetes, microvascular pathology and Alzheimer disease

  2009cited by this paper
• Chronic β-AR activation-induced calpain activation and impaired eNOS–Akt signaling mediates cardiac injury in ovariectomized female rats

  2009cited by this paper
• Calpain‐mediated truncation of GSK‐3 in post‐mortem brain samples

  2009cited by this paper
• Mechanisms of tau-induced neurodegeneration

  2009cited by this paper
• The GSK3 hypothesis of Alzheimer's disease

  2008cited by this paper
• Defective insulin signaling pathway and increased glycogen synthase kinase‐3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin

  2008cited by this paper
• Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies.

  2008cited by this paper
• Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease

  2008cited by this paper
• Wild-Type But Not FAD Mutant Presenilin-1 Prevents Neuronal Degeneration by Promoting Phosphatidylinositol 3-Kinase Neuroprotective Signaling

  2008cited by this paper
• Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.

  2008cited by this paper
• Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance

  2008cited by this paper
• Intranasal Insulin Administration Dose-Dependently Modulates Verbal Memory and Plasma Amyloid-β in Memory-Impaired Older Adults

  2008cited by this paper
• Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes

  2008cited by this paper
• Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein

  2007cited by this paper
• Down‐regulation of cAMP‐dependent protein kinase by over‐activated calpain in Alzheimer disease brain

  2007cited by this paper
• GSK-3 inhibitors for Alzheimer’s disease

  2007cited by this paper
• Indices of Metabolic Dysfunction and Oxidative Stress

  2007cited by this paper
• Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation

  2006cited by this paper
• Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

  2006cited by this paper
• Concurrent alterations of O‐GlcNAcylation and phosphorylation of tau in mouse brains during fasting

  2006cited by this paper
• The R-Ras GTPase Mediates Cross Talk between Estrogen and Insulin Signaling in Breast Cancer Cells

  2006cited by this paper
• Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.

  2006cited by this paper
• GSK-3 is essential in the pathogenesis of Alzheimer's disease

  2006cited by this paper
• Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.

  2006cited by this paper
• Risk of dementia in diabetes mellitus: a systematic review.

  2006cited by this paper
• Insulin signaling, diabetes mellitus and risk of Alzheimer disease

  2005cited by this paper
• Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology

  2005cited by this paper
• Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.

  2005cited by this paper
• Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes?

  2005cited by this paper
• Truncation and Activation of Calcineurin A by Calpain I in Alzheimer Disease Brain*

  2005cited by this paper
• O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.

  2004cited by this paper
• The source of cerebral insulin.

  2004cited by this paper
• Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease.

  2004cited by this paper
• Potential roles of insulin and IGF-1 in Alzheimer's disease.

  2003cited by this paper
• Downregulation of IRS-1 protein in thapsigargin-treated human prostate epithelial cells.

  2003cited by this paper
• Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro.

  2003cited by this paper
• Potential roles of insulin and IGF-1 in Alzheimer ’ s disease

  2003cited by this paper
• Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes

  2002cited by this paper
• Neuronal synthesized insulin roles on neural differentiation within fetal rat neuron cell cultures.

  2001cited by this paper
• Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype

  2000cited by this paper
• Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease

  1998cited by this paper
• Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain

  1997cited by this paper
• Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system.

  1996cited by this paper
• Staging of Alzheimer's disease-related neurofibrillary changes.

  1995cited by this paper
• Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration.

  1993cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein? (tau) in Alzheimer cytoskeletal pathology

  1987cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Insulin-binding sites in the rat brain: in vivo localization to the circumventricular organs by quantitative radioautography.

  1979cited by this paper
• Insulin receptors are widely distributed in the central nervous system of the rat

  1978cited by this paper
• Assay of proteins in the presence of interfering materials.

  1976cited by this paper

• Systems biology of Alzheimer's Disease: a scoping review of key pathways and mechanisms.

  2026cites this paper
• Insulin Signaling in Alzheimer’s Disease: Association with Brain Insulin Resistance

  2026influential citation
• Mechanisms and therapeutic strategies of ferroptosis in Diabetic-Associated Cognitive Dysfunction: focus on the crosstalk with apoptosis, autophagy, and pyroptosis

  2026cites this paper
• Neuroprotective Effect of Perillyl alcohol in Sporadic Alzheimer's disease in Rats.

  2025cites this paper
• Pea Peptide Modulates Abnormal Aβ Production in PC12 Cells Induced by Lead Exposure

  2025cites this paper
• Management of Alzheimer's Disease Through Nutrition

  2025cites this paper
• Antibody-conjugated polymer nanoparticles for brain cancer

  2025cites this paper
• Influence of high fructose intake on systemic and cognitive health across developmental stages: A review

  2025cites this paper
• Neuropathological links between T2DM and LOAD: systematic review and meta-analysis.

  2025cites this paper
• Insulin resistance and Alzheimer's disease: Exploring research hotspots and frontiers from a bibliometric and visual analysis (2005–2024)

  2025cites this paper
• Repurposing Saroglitazar for neurodegenerative disorders: insight into molecular signalling pathways and neuroprotective modulations

  2025cites this paper
• RAGE-Mediated Effects of Formaldehyde in Alzheimer’s Disease

  2025cites this paper
• The Multi-Dimensional Action Map of Resveratrol Against Alzheimer’s Disease: Mechanism Integration and Treatment Strategy Optimization

  2025cites this paper
• Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions

  2025cites this paper
• Insulin resistance in Alzheimer's disease: signalling mechanisms and therapeutics strategies

  2025influential citation
• O-GlcNAc cycling in neuroinflammation: From molecular mechanisms and therapeutic perspectives.

  2025cites this paper
• Amyloid beta peptides inhibit glucose transport at the blood-brain barrier by disrupting the insulin-AKT pathway

  2025cites this paper
• Target Validation Studies of PS48, a PDK-1 Allosteric Agonist, for the Treatment of Alzheimer’s Disease Phenotype in APP/PS1 Transgenic Mice

  2025cites this paper
• Blockade of insulin receptor signaling in the medullary cardiovascular centers impairs open‐loop arterial baroreflex function via attenuated neural arc in healthy male rats

  2025cites this paper
• Brain Insulin Resistance as an early target to attenuate neuroinflammation, oxidative stress and proteinopathies in Alzheimer’s Disease: A systematic review of five Natural Products

  2025cites this paper
• Pharmacological modulation of the PI3K/AKT/GSK3β axis: a new frontier in Alzheimer’s disease treatment

  2025cites this paper
• Reduction of Neuroinflammation as a Common Mechanism of Action of Anorexigenic and Orexigenic Peptide Analogues in the Triple Transgenic Mouse Model of Alzheimer´s Disease

  2025cites this paper
• Age‐Related Complement C3 Drives Memory Impairments and Associated Neuropathologies in a Mouse Model

  2025cites this paper
• Effects of Dietary Vitamin D Levels on Markers Related to Amyloidogenesis and Neuroinflammation in db/db Mice

  2025cites this paper
• Association of genetic scores related to insulin resistance with neurological outcomes in ancestrally diverse cohorts from the Trans-Omics for Precision Medicine (TOPMed) program

  2025cites this paper
• Identification of Therapeutic Potential of Hydroxychavicol Against Alzheimer's Disease: An Integrated Network Pharmacology, Molecular Docking, and Dynamic Simulation Study

  2025cites this paper
• The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases

  2024cites this paper
• Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

  2024cites this paper
• Progress in the Pathogenesis of Diabetic Encephalopathy: The Key Role of Neuroinflammation

  2024cites this paper
• Transcranial Magneto-Acoustic Stimulation Protects Synaptic Rehabilitation from Amyloid-Beta Plaques via Regulation of Microglial Functions

  2024cites this paper
• Anorexigenic neuropeptides as anti-obesity and neuroprotective agents: exploring the neuroprotective effects of anorexigenic neuropeptides

  2024cites this paper
• Mechanism of traditional Chinese medicine in elderly diabetes mellitus and a systematic review of its clinical application

  2024cites this paper
• Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications

  2024cites this paper
• Exploring the role of miR-125b-5p as a pro-inflammatory factor in Alzheimer's disease pathology

  2024cites this paper
• Lipidized analogues of the anorexigenic CART (cocaine- and amphetamine-regulated transcript) neuropeptide show anorexigenic and neuroprotective potential in mouse model of monosodium-glutamate induced obesity.

  2024cites this paper
• Navigating the Intersection: Diabetes and Alzheimer's Intertwined Relationship.

  2024cites this paper
• Euonymus hamiltonianus Extract Improves Amnesia in APPswe/Tau Transgenic and Scopolamine-Induced Dementia Models

  2024cites this paper
• True or False? Alzheimer's disease is Type 3 Diabetes: Evidences from Bench to Bedside.

  2024cites this paper
• Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration

  2024cites this paper
• Effects of a high-fat diet on cognition and brain distribution of intranasal insulin in E3 and E4 male and female mice

  2024cites this paper
• Integrated analyses of 5 mC, 5hmC methylation and gene expression reveal pathology-associated AKT3 gene and potential biomarkers for Alzheimer's disease.

  2024cites this paper
• Molecular Signaling Pathways of Quercetin in Alzheimer’s Disease: A Promising Arena

  2024cites this paper
• 肥胖与阿尔茨海默病的相关性及其作用机制（英文）

  2024cites this paper
• Brain Insulin Resistance in Neurological Disorders of Various Genesis: Current State and Treatment Approaches

  2024cites this paper
• Glucometabolic-Related Genes as Diagnostic Biomarkers and Therapeutic Targets for Alzheimer's Disease and Type 2 Diabetes Mellitus: A Bioinformatics Analysis

  2024cites this paper
• Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes

  2024cites this paper
• Diabetic Ketoacidosis Induces Tau Hyperphosphorylation in Rat Brain

  2024cites this paper
• Affective and Cognitive Impairments in Rodent Models of Diabetes

  2024cites this paper
• Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood-Brain Barrier.

  2024cites this paper
• Molecular mechanisms linking type 2 diabetes mellitus and late-onset Alzheimer's disease: A systematic review and qualitative meta-analysis.

  2024cites this paper
• Integrated transcriptome and metabolome analysis to investigate the mechanism of intranasal insulin treatment in a rat model of vascular dementia

  2023cites this paper
• Artemisin and human endometrial-derived stem cells improve cognitive function and synaptic plasticity in a rat model of Alzheimer disease and diabetes

  2023cites this paper
• LABORATORY BIOMARKERS FOR BRAIN DAMAGE IN DIABETES MELLITUS

  2023cites this paper
• Bioinformatic prediction of the molecular links between Alzheimer’s disease and diabetes mellitus

  2023cites this paper
• How Can Insulin Resistance Cause Alzheimer’s Disease?

  2023cites this paper
• Morin post-treatment surpassed calpeptin in ameliorating 3-NP-induced cortical neurotoxicity via modulation of glutamate/calpain axis, Kidins220, and BDNF/TrkB/AKT/CREB trajectory.

  2023cites this paper
• The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults

  2023cites this paper
• ACE2/ANG-(1-7)/mas receptor axis activation prevents inflammation and improves cognitive functions in streptozotocin induced rat model of Alzheimer's disease-like phenotypes.

  2023cites this paper
• Evidence of Disturbed Insulin Signaling in Animal Models of Alzheimer's Disease.

  2023cites this paper
• Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer's disease pathology: review and recommendations.

  2023cites this paper
• A Comprehensive Review of the Effects of Glycemic Carbohydrates on the Neurocognitive Functions Based on Gut Microenvironment Regulation and Glycemic Fluctuation Control

  2023cites this paper
• P25/CDK5-mediated Tau Hyperphosphorylation in Both Ipsilateral and Contralateral Cerebra Contributes to Cognitive Deficits in Post-stroke Mice

  2023cites this paper
• Amyloid-beta and tau protein beyond Alzheimer’s disease

  2023cites this paper
• Quantitative Proteomics Characterization of the Effect and Mechanism of Trichostatin A on the Hippocampus of Type II Diabetic Mice

  2023cites this paper
• Exploring the efficient natural products for Alzheimer’s disease therapy via Drosophila melanogaster (fruit fly) models

  2023cites this paper
• From Determining Brain Insulin Resistance in a Sporadic Alzheimer’s Disease Model to Exploring the Region-Dependent Effect of Intranasal Insulin

  2023cites this paper
• Multi-tissue epigenetic analysis identifies distinct associations underlying insulin resistance and Alzheimer’s disease at CPT1A locus

  2023cites this paper
• A Comparative Study about the Neuroprotective Effects of DHA-Enriched Phosphatidylserine and EPA-Enriched Phosphatidylserine against Oxidative Damage in Primary Hippocampal Neurons

  2023cites this paper
• Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives

  2022cites this paper
• Decoding Genetic Markers of Multiple Phenotypic Layers Through Biologically Constrained Genome-To-Phenome Bayesian Sparse Regression

  2022cites this paper
• Prevent Drug Leakage via the Boronic Acid Glucose-Insensitive Micelle for Alzheimer's Disease Combination Treatment.

  2022cites this paper
• Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer’s Disease

  2022cites this paper
• Causal association evaluation of diabetes with Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's disease

  2022cites this paper
• Diabetes Mellitus: A Path to Amnesia, Personality, and Behavior Change

  2022cites this paper
• The Mighty Mitochondria Are Unifying Organelles and Metabolic Hubs in Multiple Organs of Obesity, Insulin Resistance, Metabolic Syndrome, and Type 2 Diabetes: An Observational Ultrastructure Study

  2022cites this paper
• Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer’s Disease

  2022cites this paper
• Protective Role of Capsaicin in Neurological Disorders: An Overview

  2022cites this paper
• XperCT-guided Intra-cisterna Magna Injection of Streptozotocin for Establishing an Alzheimer’s Disease Model Using the Cynomolgus Monkey (Macaca fascicularis)

  2022cites this paper
• A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro

  2022cites this paper
• Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia.

  2022cites this paper
• The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress

  2022cites this paper
• Impaired insulin signalling and allostatic load in Alzheimer disease

  2022cites this paper
• The Correlation between Diabetes Mellitus and Neurodegenerative Diseases

  2022cites this paper
• BACE2: A Promising Neuroprotective Candidate for Alzheimer’s Disease

  2022cites this paper
• Current Insights on the Use of Insulin and the Potential Use of Insulin Mimetics in Targeting Insulin Signalling in Alzheimer’s Disease

  2022cites this paper
• Selective Vulnerability of the Locus Coeruleus Noradrenergic System and its Role in Modulation of Neuroinflammation, Cognition, and Neurodegeneration

  2022cites this paper
• The identities of insulin signaling pathway are affected by overexpression of Tau and its phosphorylation form

  2022cites this paper
• Amyloid Beta Peptides Inhibit Glucose Transport at the Blood-brain Barrier by Disrupting Insulin-Akt Pathway in Alzheimer’s Disease

  2022cites this paper
• Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders

  2022influential citation
• Functional consequences of brain exposure to saturated fatty acids: From energy metabolism and insulin resistance to neuronal damage

  2022cites this paper
• Brain insulin resistance and cognitive function: influence of exercise.

  2022cites this paper
• The Therapeutic Effects of Seven Lycopodium Compounds on Cell Models of Alzheimer’s Disease

  2022cites this paper
• The Role of Caspases in Alzheimer’s Disease: Pathophysiology Implications and Pharmacologic Modulation

  2022cites this paper
• Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

  2022cites this paper
• Altered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress.

  2022cites this paper
• Diabetic Encephalopathy: Role of Oxidative and Nitrosative Factors in Type 2 Diabetes

  2022cites this paper
• Prediction value of the genetic risk of type 2 diabetes on the amnestic mild cognitive impairment conversion to Alzheimer’s disease

  2022cites this paper
• Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances

  2022cites this paper
• Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM‐HET3 mice

  2022cites this paper
• Pathophysiological Association Between Diabetes Mellitus and Alzheimer's Disease

  2022cites this paper